Serum IL-1β, IL-2, and IL-6 in insulin-dependent diabetic children

Mediators of Inflammation

Volumn 2006, Issue , 2006, Pages

  Dogan, Yasar ^a   Akarsu, Saadet ^a   Ustundag, Bilal ^a   Yilmaz, Erdal ^a   Gurgoze, Metin Kaya ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ARTICLE; CELL DESTRUCTION; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION REGULATION; MALE; STATISTICAL MODEL;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MODELS, STATISTICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645222743     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI/2006/59206     Document Type: Article

References (33)

1. Kukreja A, Cost G, Marker J, et al. Multiple immunoregulatory defects in type-1 diabetes. The Journal of Clinical Investigation. 2002;109(1):131-140.
2. Karlsson Faresjo MG, Ernerudh J, Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scandinavian Journal of Immunology. 2004;59(5):517-526.
3. Hussain MJ, Maher J, Warnock T, Vats A, Peakman M, Vergani D. Cytokine overproduction in healthy first degree relatives of patients with IDDM. Diabetologia. 1998;41(3):343-349.
4. Erbagci AB, Tarakcioglu M, Coskun Y, Sivasli E, Sibel Namiduru E. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clinical Biochemistry. 2001;34(8):645-650.
5. Eizirik DL, Sandler S, Welsh N, et al. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. The Journal of Clinical Investigation. 1994;93(5):1968-1974.
6. Tchorzewski H, Glowacka E, Banasik M, Lewkowicz P, Szalapska-Zawodniak M. Activated T lymphocytes from patients with high risk of type I diabetes mellitus have different ability to produce interferon-gamma, interleukin-6 and interleukin-10 and undergo anti-CD95 induced apoptosis after insulin stimulation. Immunology Letters. 2001;75(3):225-234.
7. Rapoport MJ, Mor A, Vardi P, et al. Decreased secretion of Th2 cytokines precedes Up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. Journal of Autoimmunity. 1998;11(6):635-642.
8. El-Nawawy A, Soliman T, El-Azzouni O, et al. Interleukin-1-beta, tumor necrosis factor-alpha, insulin secretion and oral glucose tolerance in non-diabetic siblings of children with IDDM. Indian Journal of Pediatrics. 1998;65(3):455-460.
9. Netea MG, Hancu N, Blok WL, et al. Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals. Cytokine. 1997;9(4):284-287.
10. Ozer G, Teker Z, Cetiner S, et al. Serum IL-1, IL-2, TNF-alpha and INF-gamma levels of patients with type 1 diabetes mellitus and their siblings. Journal of Pediatric Endocrinology & Metabolism. 2003;16(2):203-210.
11. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochemical Pharmacology. 1998;55(8):1139-1149.
12. Davi G, Chiarelli F, Santilli F, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation. 2003;107(25):3199-3203.
13. Targher G, Zenari L, Bertolini L, Muggeo M, Zoppini G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care. 2001;24(5):956-957.
14. Kulseng B, Skjak-Braek G, Folling I, Espevik T. TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide. Scandinavian Journal of Immunology. 1996;43(3):335-340.
15. Geerlings SE, Brouwer EC, Van Kessel KC, Gaastra W, Stolk RP, Hoepelman AI. Cytokine secretion is impaired in women with diabetes mellitus. European Journal of Clinical Investigation. 2000;30(11):995-1001.
16. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sciences. 2000;67(3):291-300.
17. Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Molecular and Cellular Biochemistry. 1998;182(1-2):169-175.
18. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353(9165):1649-1652.
19. Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Molecular and Cellular Endocrinology. 2001;175(1-2):81-92.
20. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. The Journal of Clinical Investigation. 1996;97(1):238-243.
21. Schmidt AM, Hori O, Cao R, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes. 1996;45(suppl 3):S77-S80.
22. Tomoda T, Kurashige T, Taniguchi T. Imbalance of the interleukin 2 system in children with IDDM. Diabetologia. 1994; 37(5):476-482.
23. Kaye WA, Adri MN, Soeldner JS, et al. Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. The New England Journal of Medicine. 1986;315(15):920-924.
24. Lorini R, Montagna D, Lanfranchi A, et al. Alterations of in vitro interleukin 1 and 2 in diabetic children. European Journal of Pediatrics. 1989;148(8):732-734.
25. Huang W, Wang DS, Li XY, Wu WZ, Ni GC. Expression levels of IL-6 mRNA in PBMNCs from patients with IDDM, NIDDM and normals by RT-PCR procedure. Chinese Medical Journal. 1993;106(12):893-897.
26. Shah U, Karch L, Baker L, Zier KS. Low interleukin-2 synthesis by type 1 diabetics is regulated at the pretranslational level. Clinical Immunology and Immunopathology. 1991;61(2 pt 1):177-190.
27. Roncarolo MG, Zoppo M, Bacchetta R, et al. Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes. Clinical Immunology and Immunopathology. 1988;49(1):53-62.
28. Kretowski A, Mysliwiec J, Szelachowska M, Brzozowski C, Pietruczuk M, Kinalska I. In vitro secretion of interleukin 2 and expression of IL-2 receptor in peripheral blood lymphocytes in high risk of insulin-dependent diabetes mellitus subjects. Archivum Immunologiae et Therapiae Experimentalis. 1999;47(1):45-49.
29. Wagner R, Bonifacio E, Bingley PJ, Genovese S, Reinwein D, Bottazzo GF. Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes. The Clinical Investigator. 1994;72(7):494-498.
30. Gartner LA, Pfeifer MC, Albini C, Francis GL. Soluble interleukin 2 receptor levels in children with type I insulin-dependent diabetes mellitus. Annals of Clinical and Laboratory Science. 1995;25(1):44-51.
31. Zier KS, Leo MM, Spielman RS, Baker L. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes. 1984;33(6):552-555.
32. Wedrychowicz A, Dziatkowiak H, Sztefko K, Wedrychowicz A. Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes. 2004;112(8):435-439.
33. Jain SK, Kannan K, Lim G, Matthews-Greer J, McVie R, Bocchini JA Jr. Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care. 2003;26(7):2139-2143.